Back to Browse Journals » OncoTargets and Therapy » Volume 3

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Authors Steven E McCormack, Erica D Warlick

Published Date July 2010 Volume 2010:3 Pages 157—165

DOI http://dx.doi.org/10.2147/OTT.S5852

Published 22 July 2010

Steven E McCormack, Erica D Warlick

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to ­significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.

Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

The relationship between Graves’ ophthalmopathy and dry eye syndrome

Selter JH, Gire AI, Sikder S

Clinical Ophthalmology 2015, 9:57-62

Published Date: 31 December 2014

Further data on the association between Helicobacter pylori infection and primary open-angle glaucoma

Zavos C, Kountouras J

Clinical Ophthalmology 2012, 6:243-245

Published Date: 10 February 2012

Application of reticulated platelets to transfusion management during autologous stem cell transplantation

Parco S, Vascotto F

OncoTargets and Therapy 2012, 5:1-5

Published Date: 26 January 2012

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension

Inoue K, Shiokawa M, Sugahara M, Higa R, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:111-116

Published Date: 12 January 2012

Epidemiology of respiratory syncytial virus in children ≤2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study

Vladimir Tatochenko, Vasily Uchaikin, Aleksandr Gorelov, et al

Clinical Epidemiology 2010, 2:221-227

Published Date: 22 September 2010

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Ajikumar V Aryangat, John E Gerich

Vascular Health and Risk Management 2010, 6:145-155

Published Date: 9 March 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009